French drugmaker Sanofi (SASY.PA) said on Monday an upgraded version of the COVID-19 vaccine candidate it is developing with GSK (GSK.L) showed potential in two trials to protect against the virus's main variants of concern, including the Omicron BA.1 and BA.2 strains, when used as a booster shot. That sounds great!
Photo Credit: Jeremy Bezanger